These promising results enhance the need for more prospective clinical trials to assess how many ccRCC patients might have their treatment plan change after PSMA-targeted PET/CT and, more importantly, if its modification could actually lead to an improvement in their overall and disease-free survivals. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.